TidalSense is an AI-powered respiratory diagnostics company headquartered in Cambridge, UK, led by CEO Dr Ameera Patel. Its software device, N-Tidal Diagnose used in combination with N-Tidal hardware, uses AI-analysed tidal breathing — rather than the forced exhalation required by spirometry — to deliver a fast, non-invasive diagnosis of COPD in under five minutes, without specialist training or hospital-grade equipment. N-Tidal Diagnose is the first non-spirometry AI diagnostic device to receive a CE mark under EU MDR (class IIa) for COPD, and has been commissioned and used across multiple healthcare settings.
TidalSense
- Health
- Cambridge, United Kingdom
- £14m
- tidalsense.com
- Update Information
More venture news
- 24 Jul 2026

TidalSenseTidalSense secures £14m in funding from VCs to roll out AI-driven breath test for lung disease
EquityHealth - 16 Jul 2026

BeCertainBeCertain raises a £1.7m pre-seed round led by Sure Valley Ventures for AI software that helps dentists interpret X-rays
Pre-seedHealth - 9 Jul 2026

Leo Cancer CareLeo Cancer Care unlock £50m Series D led by Yu Galaxy for its upright imaging and radiotherapy platform
Series DHealth
